Are remote mental healthcare interventions cost-effective? A systematic review of economic evaluations of remote mental healthcare

Amy Clark, Rebecca Appleton, Erika Kalocsanyiova, Evdoxia Gkaintatzi, Paul McCrone

Abstract

Background

Remote interventions known as telemental health care increased in use due to the COVID-19 pandemic when social distancing requirements were in place. Whilst there is some evidence regarding the cost-effectiveness of telemental health prior to the pandemic, there is a need for further evaluation due to the increase in remote care.

Aims

To systematically review the literature to explore whether remote mental health care interventions are cost-effective in terms of incremental cost per quality adjusted life year and in relation to condition specific outcomes compared to usual care or an alternative intervention.

Method

A multilayer search strategy was conducted to build on the searches of a previous systematic review, as well as including grey literature and economic models. Six databases (PubMed, EMBASE, Cochrane Central, PsychINFO, CINAHL, and EconLit) were searched for literature relating to the cost effectiveness of telemental health. Quality appraisal was conducted for all included studies, and findings were synthesised using narrative synthesis.

Results

7386 studies were identified of which 59 met our inclusion criteria and were included in the synthesis of findings. 45 studies were rated as very good or excellent quality. Of the 59 included studies, 40 indicated that the telemental health intervention was cost-effective, whilst a further 16 suggested the intervention had potential to be cost-effective, but there was some uncertainty in the findings. Three studies reported that the intervention was not cost-effective.

Conclusions

This evidence will be used to inform practice in the UK as we respond to and recover from the COVID-19 pandemic.

Keywords: telemental health; QALYs; cost-effectiveness analysis

Introduction

Remote interventions in mental health care, or "tele-mental health" have been implemented for many years and evaluations often include assessment of cost-effectiveness. Telemental health care is defined as any interventions or modes of working where remote technology (e.g. telephone/video call/instant messaging) is used to facilitate direct communication between staff and service users, between service users and peers, or between mental health professionals in different locations.

Telemental health has the potential to result in benefits for both service users and clinicians. For example, service users have identified increased flexibility as a key advantage of remote care (1), and a recent rapid realist review (2) found that telemental health care can improve access to mental health support for people who may struggle to travel to face-to-face appointments due to disability, anxiety about travel, or caring or work responsibilities. Reported benefits for staff included an opportunity for more flexible working, less time spent travelling, and communicating with other clinicians at different sites (2, 3). However, it is important to note that telemental health is not suitable for everyone; not all service users may wish for care to be remote and inequalities and digital exclusion should be taken into consideration during the decision to offer mental health care remotely (1, 2). Clinicians have also reported finding telemental health less suitable than face-to-face care when treating trauma, or for service users in crisis or those with psychotic symptoms or severe anxiety (3).

The uptake of telemental health care increased rapidly during the COVID-19 pandemic as services moved from largely face-to-face models of care due to social distancing requirements (4, 5). However, a systematic review conducted during the early stages of the pandemic identified a lack of evidence on the cost-effectiveness of telemental health interventions (4).

Pre-pandemic evidence regarding the cost-effectiveness of telemental health was also inconclusive. An umbrella review found that in studies conducted prior to the COVID-19 pandemic, evidence regarding the cost-effectiveness of telemental health was mixed (6).

Some studies identified lower costs of telemental health care due to savings on travel time for service users, or not needing to take time off work, whereas higher costs in others were attributed to the expense of videoconferencing equipment (6). A further systematic review by Naslund et al (7) identified 26 economic evaluations of telepsychiatry programmes, also prior to the COVID-19 pandemic. They found that 60% reported telepsychiatry programmes to be less expensive and 32% reported they were more expensive than usual care, again primarily due to costs of technology and equipment. This review was limited to peer-reviewed studies that used primary data collection and therefore economic models were excluded.

This proposed review therefore aims to build on Naslund et al (7) and bring together further evidence on economic evaluations of remote mental healthcare. We originally set out to answer the following secondary review questions: (i) Does cost-effectiveness of remote mental health care interventions differ by subgroup? (ii) Does cost-effectiveness of remote mental health care interventions differ by model type? (iii) What is the impact of remote technology for staff communication on costs for the health and social care system? (iv) What is the impact of remote technology for mental healthcare interventions on costs for the health and social care system? (v) How is the amount of contact time between service users and mental health care professionals affected by remote interventions? However, given the data reported in the selected studies only research questions ii and iv will be addressed in this paper.

Methods

The review was registered on International prospective register of Systematic Reviews (PROSPERO) ID: CRD42020216755. We developed a multilayer search strategy to capture both new evidence published since the completion of the Naslund et al. (7) searches on 16 March 2018 and to cover additional sources of information excluded by these authors, namely grey literature and simulation models. We used the same search criteria as outlined in Naslund et al. (7) to identify any relevant peer reviewed literature published since 16

March 2018. The following six databases were searched on 8-10 December 2020: PubMed (MEDLINE), EMBASE, Cochrane Central, PsychINFO (EBSCOhost), CINAHL, and EconLit[1].

An example of the search terms used, as per Naslund et al. (7), is reported in Table S1[2] of the Supplementary Material. To identify economic models, which were excluded by Naslund et al. (7), the same strategy was used but with a different date range (January 2000 – October 2020) and two additional search terms added to Table S1: "model OR simulation". Grey literature databases were searched from 1 January 2000 to 31 October 2020 for terms related to "tele" "mental health" and "costs" as outlined in Table S2. MedNAR and Google were also searched using the following terms to improve relevance of results: "cost effective" AND (tele* OR telehealth OR telepsychiatry OR remote OR technology OR digital) AND mental. Records identified in the search were uploaded to Rayyan QCRI, a web-based reference manager system for collaborative systematic review, for de-duplication and blinded screening and study selection.

Study selection criteria

After de-duplication, the results were pre-screened by three student research assistants (MT, SS, and JP). A 25 per cent sample was selected at random and checked for accuracy by the second author (EK). The titles and abstracts of the remaining studies were screened in duplicate by three reviewers (AC, EK and JB) against the eligibility criteria shown in Table 1. Disagreements and records marked as undecided were resolved by discussion or a consensus involving a third author.

In the process of abstract and title screening, we identified 21 peer-reviewed cost effectiveness studies published prior to March 2018 which appeared eligible according to the study selection criteria outlined in Naslund et al. (7) but were not included in their review. Given that these studies were identified in grey literature databases not considered

[1] The following databases used in Naslund et al. (2020) were not included in this review due to organisational access and the number of duplicates already identified: Web of Science, Health Economic Evaluations Database, Cost-Effectiveness Analysis Registry, Research Papers in Economics (RcPEc), and European Network of Health Economic Evaluation Database (EURONHEED).
[2] In CINAHL we were unable to apply MeSH terms, and in EconLit the simplified grey literature strategy was used (see Table S2).

by Naslund et al. (7), we decided to assess them for inclusion along with the other studies retained for full text screening.

Where full text was not available, the corresponding authors were contacted. If an answer was not obtained following a reminder and a 3-month waiting period, the study was excluded. Reference list searching was undertaken by the second author (EK). The search and study selection process has been documented in Figure 1 using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA guidelines (8).

Data extraction and analysis

Partial data extraction was undertaken by three student research assistants (SS, HA and FB) and completed by two of the authors (EG and AC). For 25 per cent of studies a third team member extracted the data in duplicate. Following data extraction, the studies were sorted by intervention type, categorised into study design type (i.e., model/cost utility analysis or cost-effectiveness analysis), and we considered whether the evidence favoured the intervention or not. Given the heterogeneity of the retained studies meta-analysis was not undertaken. As with most reviews of economic evaluations, the results are presented in the form of a narrative synthesis (9).

Quality appraisal

We used the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) (10) checklist to assess different aspects of the retained studies' quality and reporting. The checklist contains 24 items and accompanying recommendations (see Table S3). The overall quality of evidence was assessed using GRADE certainty ratings (11). Final quality was rated high, moderate, low, or very low. The quality assessment was completed by EK. A 25 per cent sample was selected at random and assessed in duplicate by AC. Where results differed, consensus was reached through discussion or the involvement of a third assessor (PM).

Results

The initial search identified 7386 papers. Duplicates were then removed and after screening by three research assistants (MT, SS, and JP) a further 2462 records were excluded. The random sample of 25% used for checking revealed no conflicts. After the duplicate screening of remaining papers, disagreements (n=26) and records marked as undecided (n=77) were resolved. A total of 59 unique studies met the inclusion criteria (Figure 1). Eight full text papers could not be obtained and reference lists revealed no extra studies. Search 1 identified four grey literature reports, search 2 identified 41 unique studies from the updated Naslund et al (7) search, and search 3 found a further 14 studies of economic models. The non-modelling studies enrolled 5-1514 participants. The USA was the setting for most studies (16), followed by Sweden (10) and the UK (8). For more detailed study characteristics see Table 3.

The majority (n=40) of included studies found that the telemental health intervention was cost-effective. A further 16 studies indicated that there was some uncertainty around whether the intervention was more cost-effective than the comparator, or that the intervention had potential to be cost-effective but there were some biases in how the study was conducted. Only three studies found that the intervention was less cost-effective than the comparator.

Table 3 shows that the most common interventions were internet-based therapy and videoconferencing. Twenty-one studies evaluated some form of internet-based/delivered therapy (usually cognitive behavioural therapy). QALYs were used in 13 of these studies, DALYs in two studies, productivity losses in one study, and clinically specific measures in the remaining studies. In eight studies the costs for the intervention were lower than the comparator and outcomes were better, indicating a situation of dominance (12-19). In five studies where the intervention had higher costs and produced better outcomes, the ICER was relatively low and indicated cost-effectiveness (20-24). Two studies indicated that therapy was not cost-effective (25, 26).

Videoconferencing and video support to clinicians and patients was evaluated in eight studies. Four of these did not use an outcome measure in the economic analysis and all showed cost savings (27-30). Two other studies reported similar outcomes and lower costs (31, 32). One study, evaluating video coaching for carers of children with behavioural problems, found it to cost saving and outcome improving (27). Another study, found videoconferencing to result in costs per improvement in depression of $222 and per improvement in competence of $437 (33).

Studies that evaluated other remote working interventions usually demonstrated costs savings, dominance (costs savings and better outcomes), or higher costs and better outcomes that justified the extra expense. The study by Pot-Kolder et al (34) found the cost per QALY of virtual reality-based CBT for people with psychosis and paranoid symptoms to be nearly €50,000. However, this was deemed to be cost-effective based on a threshold of €80,000 per QALY for conditions such as this.

The number of studies taking a societal perspective was 27 with 22 taking a healthcare perspective. QALYs were reported in 31 studies and DALYs in four. The reporting quality of each included article was assessed using the 24-item CHEERS checklist: the proportion of studies that met the criteria for each item is shown in Figure 2. 28 studies were of excellent quality, meaning that they addressed satisfactorily at least 90% of applicable checklist items (12, 13, 15-17, 20-22, 24-27, 31, 34-47). 17 studies (14, 19, 23, 48-61) were of very good quality (70-<90%), and further five studies (18, 62-65); had an acceptable quality of reporting (> 60%). The remaining nine studies failed to address or addressed only partially ten or more relevant checklist items. The least reported items were study perspective (item # 6), currency, price date, and conversion (item # 14), the effects of uncertainty (item # 20), and potential conflicts of interest (item # 24). About 40 % of the studies failed to describe fully the characteristics of the base-case population (item # 4), and the sources and methods used to establish clinical effectiveness (item # 11). Similarly, only 80% of the studies reported in sufficient detail the approaches and data sources used to estimate costs (item # 13) and the analytical methods which supported their evaluation (item # 17). Data for subgroup analyses was not available in most cases (item # 21). Finally, approximately half of the studies either did not name its funding source or failed to disclose the funder's role in

the identification, design, conduct, and reporting of the analysis. The detailed performance of each included study for the CHEERS checklist (10) is shown in Table S4 of the Supplement. The overall quality of evidence was assessed using GRADE certainty ratings (11). The assigned ratings shown in Table 2 were based on the quality of the economic evidence. Overall, there was an over reliance on single-study based estimates. The certainty of evidence was downgraded due to several factors, including imprecision (effect estimates coming from one study with a small sample), risk of bias (narrow perspective, cost omissions related to comorbidity, healthcare utilisation and other relevant aspects, losses to follow-up, short time horizon and limited sensitivity analysis), indirectness (cost estimates based on secondary sources rather than actual resource use, and high percentage of missing data imputed) and potential sponsor bias. The main reasons for downgrading for each study rated as moderate or below are summarised in Table 2.

Discussion

This systematic review identified 59 studies to build on the findings from Naslund et al (7) regarding the impact of remote technology for mental healthcare interventions in terms of costs and cost-effectiveness. The review by Naslund et al (7) included 26 studies and found good evidence for cost savings associated with telepsychiatry but somewhat limited evidence of cost-effectiveness. We included a broader range of studies and again these suggest that remote working can result in reduced costs but we also identified a reasonable number of full economic evaluations where remote working was either dominant (cost saving and outcome improving) or to result in incremental cost-effectiveness ratios that are below acceptable thresholds. However, as with Naslund et al (7), the studies were markedly heterogeneous with very different designs and perspectives.

The greatest number of studies evaluated some form of internet-delivered therapy (usually cognitive behavioural therapy). These tended to be cost effective as were the various forms of videoconferencing (although many of the latter were limited to cost comparisons).

The perspective taken in the studies was fairly evenly split between a societal perspective (generally meaning that lost work time was included) and a healthcare perspective. This is likely to reflect both the expected benefits of remote working but also the different ways in which healthcare decisions are made in each country. While the latter consideration is important, from an economic point of view we might expect remote working to save patient time and this may include time in work. As such, a societal perspective seems appropriate in this area.

Decision makers often base recommendations on the relationship between costs and QALYs and the studies reviewed here reflect this with 31 using QALYs as the main economic outcome measure. This is interesting especially given some concerns over the use of QALYs in mental health research (66, 67). Most of these concerns though are with the sue of QALYs in studies of interventions for schizophrenia and other severe mental illnesses. As stated above, internet-based cognitive behavioural therapy was most commonly evaluated, and this usually provided for people with depression or anxiety. QALYs do tend to work reasonably well for these conditions.

Implications

Evaluations of remote working interventions for mental health problems have been criticised for being methodologically limited and this may have held back developments in this area (68). It is from this review that the amount of cost-effectiveness research has increased substantially, and the evidence base is getting stronger. However, methodological issues persist.

The COVID-19 pandemic has clearly led to remote working being given more prominence. While services will to some extent revert back to usual ways of working, some aspects of care delivery that have emerged since early 2020 will most likely remain. In the UK, the charity Mind has identified challenges including the extent to which people have good access to engage with digital approaches, the quality of care delivered in this way not always being of a high standard, and potential breaches of confidentiality (69). As demands on health services continue to increase, it is likely that innovations such as those reviewed here will be needed more and more and it is thus encouraging that on balance they do appear to represent reasonable value for money.

Limitations

We based our search terms on those used previously by Naslund et al (7). This was appropriate in that we were wanting to update that review but also to include studies from a broader range of sources. However, the strategy may have been too specific and might have missed economic models published prior to 2018. Some terms were excluded that could have been relevant, particularly those relating to the use of social media and platforms such as Zoom or Microsoft Teams.

Another limitation is that some interventions/services only included remote working as a component of a wider package of care or support. It was appropriate to include such studies in order to obtain a broad overview of remote working but identifying the specific impact of remote working is challenging in such studies.

As with other reviews of economic evaluations, included studies were very heterogeneous. This meant that we could only provide a narrative review rather than a more formal synthesis of findings.

Conclusion

This review has found numerous studies assessing the costs and cost-effectiveness of remote working interventions in mental health. Such approaches appear to be cost-effective although methodological quality of studies needs to be enhanced.

Data Availability

Data availability is not applicable to this article as no new data were created or analysed in this study.

Author Contributions

The study was developed by AC and PM. Papers were identified and data extracted by AC, EK, EG, and PM. The manuscript was written by AC, RA, EK, EG and PM.

Funding

This paper presents independent research commissioned and funded by the National Institute for Health Research (NIHR) Policy Research Programme, conducted by the NIHR Policy Research Unit (PRU) in Mental Health. AC was funded through an NIHR research fellowship. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or its arm's length bodies, or other government departments.

Declaration of interest

None

Acknowledgements

Joseph Botham assisted with the initial search and data extraction. UCL post-graduate placement students provided invaluable contribution to this study. Initial title and abstract screening was completed by Magdalena Tomoskova, Jiping Mo and Sypros Spyridonids. Data extraction support was completed by Hana Afra, Spyros Spyridonidis and Fatima Bashir.

References

1. Vera San Juan N, Shah P, Schlief M, Appleton R, Nyikavaranda P, Birken M, et al. Service user experiences and views regarding telemental health during the COVID-19 pandemic: A co-produced framework analysis. PloS one. 2021;16(9):e0257270.
2. Schlief M, Saunders KR, Appleton R, Barnett P, San Juan NV, Foye U, et al. What works for whom with telemental health? A rapid realist review. medRxiv. 2022.
3. Feijt M, De Kort Y, Bongers I, Bierbooms J, Westerink J, IJsselsteijn W. Mental health care goes online: Practitioners' experiences of providing mental health care during the COVID-19 pandemic. Cyberpsychology, Behavior, and Social Networking. 2020;23(12):860-4.
4. Appleton R, Williams J, San Juan NV, Needle JJ, Schlief M, Jordan H, et al. Implementation, adoption, and perceptions of telemental health during the COVID-19 pandemic: systematic review. Journal of medical Internet research. 2021;23(12):e31746.
5. Zangani C, Ostinelli EG, Smith KA, Hong JS, Macdonald O, Reen G, et al. Impact of the COVID-19 Pandemic on the Global Delivery of Mental Health Services and Telemental Health: Systematic Review. JMIR mental health. 2022;9(8):e38600.
6. Barnett P, Goulding L, Casetta C, Jordan H, Sheridan-Rains L, Steare T, et al. Implementation of telemental health services before COVID-19: rapid umbrella review of systematic reviews. Journal of medical Internet research. 2021;23(7):e26492.
7. Naslund JA, Mitchell LM, Joshi U, Nagda D, Lu C. Economic evaluation and costs of telepsychiatry programmes: A systematic review. Journal of telemedicine and telecare. 2022;28(5):311-30.
8. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic reviews. 2021;10(1):1-11.
9. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews. A product from the ESRC methods programme Version. 2006;1(1):b92.
10. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. International journal of technology assessment in health care. 2013;29(2):117-22.
11. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Bmj. 2008;336(7650):924-6.
12. Lindsäter E, Axelsson E, Salomonsson S, Santoft F, Ljótsson B, Åkerstedt T, et al. Cost-effectiveness of therapist-guided internet-based cognitive behavioral therapy for stress-related disorders: secondary analysis of a randomized controlled trial. Journal of medical Internet research. 2019;21(9):e14675.
13. Baumann M, Stargardt T, Frey S. Cost–utility of internet-based cognitive behavioral therapy in unipolar depression: A Markov model Simulation. Applied health economics and health policy. 2020;18(4):567-78.
14. Mohr DC, Lattie EG, Tomasino KN, Kwasny MJ, Kaiser SM, Gray EL, et al. A randomized noninferiority trial evaluating remotely-delivered stepped care for depression using internet cognitive behavioral therapy (CBT) and telephone CBT. Behaviour Research and Therapy. 2019;123:103485.
15. Jolstedt M, Wahlund T, Lenhard F, Ljótsson B, Mataix-Cols D, Nord M, et al. Efficacy and cost-effectiveness of therapist-guided internet cognitive behavioural therapy for

paediatric anxiety disorders: a single-centre, single-blind, randomised controlled trial. The Lancet Child & Adolescent Health. 2018;2(11):792-801.
16. van Luenen S, Kraaij V, Garnefski N, Spinhoven P, van den Akker–van ME. Cost-utility of a guided Internet-based intervention in comparison with attention only for people with HIV and depressive symptoms: A randomized controlled trial. Journal of psychosomatic research. 2019;118:34-40.
17. Lalouni M, Ljótsson B, Bonnert M, Ssegonja R, Benninga M, Bjureberg J, et al. Clinical and cost effectiveness of online cognitive behavioral therapy in children with functional abdominal pain disorders. Clinical Gastroenterology and Hepatology. 2019;17(11):2236-44. e11.
18. ZHOU Y-X. Efficacy and cost-effectiveness of internet-based cognitive behavioral therapy for obsessive-compulsive disorder. Journal of Shanghai Jiaotong University (Medical Science). 2019:622-8.
19. Kumar S, Jones Bell M, Juusola JL. Mobile and traditional cognitive behavioral therapy programs for generalized anxiety disorder: A cost-effectiveness analysis. PloS one. 2018;13(1):e0190554.
20. Hedman E, Andersson E, Ljótsson B, Axelsson E, Lekander M. Cost effectiveness of internet-based cognitive behaviour therapy and behavioural stress management for severe health anxiety. BMJ open. 2016;6(4):e009327.
21. Nobis S, Ebert DD, Lehr D, Smit F, Buntrock C, Berking M, et al. Web-based intervention for depressive symptoms in adults with types 1 and 2 diabetes mellitus: a health economic evaluation. The British Journal of Psychiatry. 2018;212(4):199-206.
22. Kraepelien M, Mattsson S, Hedman-Lagerlöf E, Petersson IF, Forsell Y, Lindefors N, et al. Cost-effectiveness of internet-based cognitive–behavioural therapy and physical exercise for depression. BJPsych Open. 2018;4(4):265-73.
23. Mihalopoulos C, Shih STF, Kiropoulos L, Blashki G, Meadows G, Gunn J. Exploratory economic analyses of two primary care mental health projects: implications for sustainability. Medical Journal of Australia. 2005;183:S73-S6.
24. Richards D, Bower P, Chew-Graham C, Gask L, Lovell K, Cape J, et al. Clinical effectiveness and cost-effectiveness of collaborative care for depression in UK primary care (CADET): a cluster randomised controlled trial. Health Technology Assessment. 2016;20(14):1-192.
25. Kolovos S, van Dongen JM, Riper H, Buntrock C, Cuijpers P, Ebert DD, et al. Cost effectiveness of guided Internet-based interventions for depression in comparison with control conditions: An individual–participant data meta-analysis. Depression and anxiety. 2018;35(3):209-19.
26. Axelsson E, Andersson E, Ljótsson B, Hedman-Lagerlöf E. Cost-effectiveness and long-term follow-up of three forms of minimal-contact cognitive behaviour therapy for severe health anxiety: Results from a randomised controlled trial. Behaviour research and therapy. 2018;107:95-105.
27. Olthuis JV, McGrath PJ, Cunningham CE, Boyle MH, Lingley-Pottie P, Reid GJ, et al. Distance-delivered parent training for childhood disruptive behavior (Strongest Families™): a randomized controlled trial and economic analysis. Journal of abnormal child psychology. 2018;46(8):1613-29.
28. Jardine I, Griffiths J, Kelly J, Navein J. Telemedicine options appraisal for a health district--a strategic clinical and business case. J Telemed Telecare. 2001;7 Suppl 1:16-9.

29. Mielonen M-L, Ohinmaa A, Moring J, Isohanni M. Psychiatric inpatient care planning via telemedicine. Journal of Telemedicine and Telecare. 2000;6(3):152-7.
30. Shore JH, Brooks E, Savin DM, Manson SM, Libby AM. An economic evaluation of telehealth data collection with rural populations. Psychiatr Serv. 2007;58(6):830-5.
31. Egede LE, Dismuke CE, Walker RJ, Acierno R, Frueh BC. Cost-effectiveness of behavioral activation for depression in older adult veterans: in-person care versus telehealth. The Journal of clinical psychiatry. 2018;79(5):3853.
32. Wilson JA. Psychoeducational dissemination across distance: The viability of telehealth with the deaf population: Brigham Young University; 2008.
33. Shaw CA, Williams KN, Lee RH, Coleman CK. Cost-effectiveness of a telehealth intervention for in-home dementia care support: Findings from the FamTechCare clinical trial. Research in nursing & health. 2021;44(1):60-70.
34. Pot-Kolder R, Veling W, Geraets C, Lokkerbol J, Smit F, Jongeneel A, et al. Cost-effectiveness of virtual reality cognitive behavioral therapy for psychosis: health-economic evaluation within a randomized controlled trial. Journal of medical Internet research. 2020;22(5):e17098.
35. Ontario HQ. Internet-delivered cognitive behavioural therapy for major depression and anxiety disorders: a health technology assessment. Ontario health technology assessment series. 2019;19(6):1.
36. Axelsson E, Andersson E, Ljótsson B, Björkander D, Hedman-Lagerlöf M, Hedman-Lagerlöf E. Effect of internet vs face-to-face cognitive behavior therapy for health anxiety: a randomized noninferiority clinical trial. JAMA psychiatry. 2020;77(9):915-24.
37. Hedman-Lagerlöf M, Hedman-Lagerlöf E, Ljótsson B, Wicksell RK, Flink I, Andersson E. Cost-effectiveness and cost-utility of internet-delivered exposure therapy for fibromyalgia: results from a randomized, controlled trial. The Journal of Pain. 2019;20(1):47-59.
38. Kaltenthaler E, Brazier J, De Nigris E, Tumur I, Ferriter M, Beverley C, et al. Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England). 2006;10(33):iii, xi-xiv, 1.
39. Klein NS, Bockting CL, Wijnen B, Kok GD, van Valen E, Riper H, et al. Economic evaluation of an internet-based preventive cognitive therapy with minimal therapist support for recurrent depression: randomized controlled trial. Journal of medical Internet research. 2018;20(11):e10437.
40. Kooistra LC, Wiersma JE, Ruwaard J, Neijenhuijs K, Lokkerbol J, van Oppen P, et al. Cost and effectiveness of blended versus standard cognitive behavioral therapy for outpatients with depression in routine specialized mental health care: pilot randomized controlled trial. Journal of medical Internet research. 2019;21(10):e14261.
41. Lee Y-C, Gao L, Dear BF, Titov N, Mihalopoulos C. The cost-effectiveness of the online MindSpot Clinic for the treatment of depression and anxiety in Australia. J Ment Health Policy Econ. 2017;20(4):155-66.
42. Morriss R, Patel S, Malins S, Guo B, Higton F, James M, et al. Clinical and economic outcomes of remotely delivered cognitive behaviour therapy versus treatment as usual for repeat unscheduled care users with severe health anxiety: a multicentre randomised controlled trial. BMC medicine. 2019;17(1):1-13.

43. Richards D, Enrique A, Eilert N, Franklin M, Palacios J, Duffy D, et al. A pragmatic randomized waitlist-controlled effectiveness and cost-effectiveness trial of digital interventions for depression and anxiety. NPJ digital medicine. 2020;3(1):1-10.
44. Smit F, Lokkerbol J, Riper H, Majo C, Boon B, Blankers M. Modeling the cost-effectiveness of health care systems for alcohol use disorders: how implementation of eHealth interventions improves cost-effectiveness. Journal of Medical Internet Research. 2011;13(3):e1694.
45. Holst A, Björkelund C, Metsini A, Madsen J-H, Hange D, Petersson E-LL, et al. Cost-effectiveness analysis of internet-mediated cognitive behavioural therapy for depression in the primary care setting: results based on a controlled trial. BMJ open. 2018;8(6):e019716.
46. Kählke F, Buntrock C, Smit F, Berking M, Lehr D, Heber E, et al. Economic evaluation of an internet-based stress management intervention alongside a randomized controlled trial. JMIR mental health. 2019;6(5):e10866.
47. Mukuria C, Brazier J, Barkham M, Connell J, Hardy G, Hutten R, et al. Cost-effectiveness of an improving access to psychological therapies service. The British Journal of Psychiatry. 2013;202(3):220-7.
48. Dowd WN, Cowell AJ, Regan D, Moran K, Slevin P, Doyle G, et al. An exploratory cost-effectiveness analysis of the connected health intervention to improve care for people with dementia: a simulation analysis. Health Services and Outcomes Research Methodology. 2018;18(1):47-62.
49. Lerner D, Adler DA, Rogers WH, Ingram E, Oslin DW. Effect of adding a work-focused intervention to integrated care for depression in the Veterans Health Administration: a randomized clinical trial. JAMA network open. 2020;3(2):e200075-e.
50. Lobban F, Akers N, Appelbe D, Chapman L, Collinge L, Dodd S, et al. Clinical effectiveness of a web-based peer-supported self-management intervention for relatives of people with psychosis or bipolar (REACT): online, observer-blind, randomised controlled superiority trial. BMC psychiatry. 2020;20(1):1-16.
51. Lokkerbol J, Adema D, Cuijpers P, Reynolds III CF, Schulz R, Weehuizen R, et al. Improving the cost-effectiveness of a healthcare system for depressive disorders by implementing telemedicine: a health economic modeling study. The American Journal of Geriatric Psychiatry. 2014;22(3):253-62.
52. Naveršnik K, Mrhar A. Cost-effectiveness of a novel e-health depression service. Telemedicine and e-Health. 2013;19(2):110-6.
53. Osborne D, Meyer D, Moulding R, Kyrios M, Bailey E, Nedeljkovic M. Cost-effectiveness of internet-based cognitive-behavioural therapy for obsessive-compulsive disorder. Internet interventions. 2019;18:100277.
54. Pil L, Pauwels K, Muijzers E, Portzky G, Annemans L. Cost-effectiveness of a helpline for suicide prevention. Journal of telemedicine and telecare. 2013;19(5):273-81.
55. Thase ME, McCrone P, Barrett MS, Eells TD, Wisniewski SR, Balasubramani G, et al. Improving cost-effectiveness and access to cognitive behavior therapy for depression: providing remote-ready, computer-assisted psychotherapy in times of crisis and beyond. Psychotherapy and psychosomatics. 2020;89(5):307-13.
56. Dukhovny D, Dennis C-L, Hodnett E, Weston J, Stewart DE, Mao W, et al. Prospective economic evaluation of a peer support intervention for prevention of postpartum depression among high-risk women in Ontario, Canada. American journal of perinatology. 2013;30(08):631-42.

57. Joesch JM, Sherbourne CD, Sullivan G, Stein MB, Craske MG, Roy-Byrne P. Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care. Psychological medicine. 2012;42(9):1937-48.
58. Kafali N, Cook B, Canino G, Alegria M. Cost-effectiveness of a randomized trial to treat depression among Latinos. The journal of mental health policy and economics. 2014;17(2):41.
59. Simon GE, VonKorff M, Rutter C, Wagner E. Randomised trial of monitoring, feedback, and management of care by telephone to improve treatment of depression in primary care. Bmj. 2000;320(7234):550-4.
60. Simon GE, Manning WG, Katzelnick DJ, Pearson SD, Henk HJ, Helstad CP. Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Archives of general psychiatry. 2001;58(2):181-7.
61. Wang PS, Patrick A, Avorn J, Azocar F, Ludman E, McCulloch J, et al. The costs and benefits of enhanced depression care to employers. Archives of General Psychiatry. 2006;63(12):1345-53.
62. Horn BP, Barragan GN, Fore C, Bonham CA. A cost comparison of travel models and behavioural telemedicine for rural, Native American populations in New Mexico. Journal of Telemedicine and Telecare. 2016;22(1):47-55.
63. Topooco N, Berg M, Johansson S, Liljethörn L, Radvogin E, Vlaescu G, et al. Chat-and internet-based cognitive–behavioural therapy in treatment of adolescent depression: randomised controlled trial. BJPsych open. 2018;4(4):199-207.
64. Yilmaz SK, Horn BP, Fore C, Bonham CA. An economic cost analysis of an expanding, multi-state behavioural telehealth intervention. Journal of telemedicine and telecare. 2019;25(6):353-64.
65. Mlcoch T, Kruntorádová K, Mandelíková M, Dolezal T. Cost-Effectiveness Analysis of the Information Technology Aided Relaps Prevention Programme in Schizophrenia (Itareps) in the Czech Republic. Value in Health. 2015;18(7):A410.
66. Chisholm D, Healey A, Knapp M. QALYs and mental health care. Social Psychiatry and Psychiatric Epidemiology. 1997;32(2):68-75.
67. McCrone P, Patel A, Knapp M, Schene A, Koeter M, Amaddeo F, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ. 2009;12(1):27-31.
68. Aboujaoude E. Telemental health: why the revolution has not arrived. World Psychiatry. 2018;17(3):277.
69. Mind. Digital services for people with mental health problems and digital exclusion during the coronavirus pandemic. Mind; 2020.
70. Lee Y, Barendregt J, Stockings E, Ferrari A, Whiteford H, Patton G, et al. The population cost-effectiveness of delivering universal and indicated school-based interventions to prevent the onset of major depression among youth in Australia. Epidemiology and psychiatric sciences. 2017;26(5):545-64.
71. Harley J. Economic evaluation of a tertiary telepsychiatry service to an island. J Telemed Telecare. 2006;12(7):354-7.
72. Segal ZV, Dimidjian S, Beck A, Boggs JM, Vanderkruik R, Metcalf CA, et al. Outcomes of Online Mindfulness-Based Cognitive Therapy for Patients With Residual Depressive Symptoms: A Randomized Clinical Trial. JAMA Psychiatry. 2020;77(6):563-73.

73. Health Quality Ontario. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment. Ont Health Technol Assess Ser. 2019;19(6):1-199.
74. Blankers M, Nabitz U, Smit F, Koeter MW, Schippers GM. Economic evaluation of internet-based interventions for harmful alcohol use alongside a pragmatic randomized controlled trial. Journal of medical Internet research. 2012;14(5):e2052.
75. Abhulimen S, Hirsch A. Quantifying the economic impact of a digital self-care behavioral health platform on Missouri Medicaid expenditures. Journal of Medical Economics. 2018;21(11):1084-90.
76. Lange K. Introducing Telepsychiatry into Routine Practice in an Emergency Department Psychiatric Service. Oxford Health NHS Foundation Trust; 2017.

Table 1: Eligibility criteria.

<table>
<tr><td>1</td><td>Participants</td><td colspan="2">People (all age groups) in receipt of mental healthcare, or staff working within mental healthcare in any setting. This included individuals with any DSM/ICD mental disorder.</td></tr>
<tr><td>2</td><td>Intervention</td><td colspan="2">Any form of spoken or written communication delivered via remote technology such as via telephone, video calls, internet software, or messaging where a mental healthcare professional, service user, family member, carer or mental health advocate is present. This included peer to peer interaction and staff to staff interaction for example through the delivery of remote supervision.</td></tr>
<tr><td>3</td><td>Comparator</td><td colspan="2">Usual care/practice or other active treatment (which may include “do nothing” or waiting lists).</td></tr>
<tr><td></td><td></td><td>Grey literature</td><td>Peer-reviewed literature</td></tr>
<tr><td rowspan="3">4</td><td rowspan="3">Design</td><td rowspan="3">Any assessment of costs or resource use, or an economic evaluation where both costs and outcomes were reported and a linkage was made between these.</td><td>Any experimental, observational naturalistic or feasibility studies involving primary data collection published since March 2018 which included an assessment of costs or resource use or an economic evaluation where both costs and outcomes were reported and a linkage was made.</td></tr>
<tr><td>OR</td></tr>
<tr><td>Studies published since 2000 that include a formal link between costs and outcomes in an economic model only.</td></tr>
</table>

Table 2: Summary of GRADE certainty ratings.

Authors (year)	GRADE rating	Reasons for downgrading and/or upgrading the quality of evidence	Authors (year)	GRADE rating	Reasons for downgrading and/or upgrading the quality of evidence
Lee et al. (2017) (70)	HIGH		Mohr et al. (2019) (14)	MODERATE	*Limited cost analysis (only therapist cost considered)*
Lokkerbol et al. (2014) (51)	HIGH		Kooistra et al. (2019) (40)	HIGH	
Naversnik et al. (2013) (52)	MODERATE	*Model inputs with moderate/unclear risk of bias*	Baumann (2020) (13)	HIGH	
Osborne at al. (2019) (53)	MODERATE	*Limited cost analysis (healthcare costs not considered); productivity savings assumed rather than measured, limited sensitivity analysis*	Richards (2020) (43)	HIGH	
Pil et al. (2013) (54)	MODERATE	*Incidence rates, relative risk reduction, and cost estimates extracted from studies conducted in other countries*	Yilmaz et al. (2019) (64)	LOW	*limited cost data, mostly extracted from secondary sources, no information about the target population or its health outcomes in the compared models*
Kählke et al (2019) (46)	HIGH		Lindsater et al. (2019) (12)	MODERATE	*Actively discouraged WLC to not seek alternative therapies which may risk biased outcome reporting*
Axelsson (2020) (36)	HIGH		Shaw et al. (2020) (33)	LOW	*Biased selection of outcomes for the cost-effectiveness analysis, no extrapolations of costs related to relevant healthcare outcomes or societal costs (e.g., informal caregiving hours)*
Kolovos et al. (2018) (25)	HIGH		Thase et al. (2020) (55)	MODERATE	*Lack of discussion on sampling uncertainty (no CEAC provided), missing data method not stated in CEA*
Dowd et al. (2018) (48)	MODERATE	*Effect estimate comes from a small 6-week feasibility study; direct estimates replaced by hypothetical scenarios that represented a large-scale deployment of technology*	Olthuis et al. (2018) (27)	MODERATE	*Cost estimates based on secondary sources rather than the actual costs paid for services/medication, findings are limited by the exclusion of a relevant sub-group of children and the study's homogenous sample*
Pot-Kolder et al. (2020) (34)	HIGH		Richards (2016) (24)	HIGH	
Smit et al. (2011) (44)	HIGH		Hedman et al. (2016) (20)	HIGH	
Lerner et al. (2020) (49)	LOW	*Limited cost analysis (only one secondary measure, loss of productivity, used in ROI assessment)*	Joesch et al. (2012) (57)	MODERATE	*Large sample but substantial missing data (cost data from 70% of the baseline sample), short follow-up, limited sensitivity analysis*
Hedman-Lagerlof et al. (2019) (37)	HIGH		Harley (2006) (71)	LOW	*Limited cost analysis (cost savings based on travel and equipment purchase only), limited information about the target population and its health outcomes*
Lalouni et al. (2019) (17)	HIGH		Jardine et al. (2001) (28)	LOW	*No information about the sources used to estimate resource use/costs, limited description of analytical methods, assumptions not specified*
Segal et al. (2020) (72)	LOW	*Limited cost analysis (only average salary costs/participant in the intervention)*	Health Quality Ontario (2019) (73)	HIGH	
Lobban et al. (2020) (50)	MODERATE	*Limited cost analysis (only development and RD costs considered)*	Mielonen et al. (2000) (29)	LOW	*Limited cost analysis (only equipment and travel cost savings considered)*

Kaltenthaler et al. (2006) (38)	HIGH		Blankers et al. (2012) (74)	HIGH	
Kraepelien et al. (2018) (22)	HIGH		Dukhovny et al. (2013) (56)	MODERATE	*Homogenous sample (generally well educated and high income), short follow-up, potential recall bias in cost estimates, screening tool (EPDS) used as primary marker of effectiveness*
Mihalopoulos et al. (2005) (23)	MODERATE	*Limited information about target population, outcomes, and efficacy*	Kafali et al. (2014) (58)	MODERATE	*Did not consider use of general medical services, short follow-up, limited discussion of uncertainty*
Horn et al. (2016) (62)	MODERATE	*No information about the target population or its health outcomes*	Mukuria (2013) (47)	MODERATE	*Imbalanced samples at intervention and comparator sites, participants at comparator site possibly not representative of the population, high participants attrition at the intervention site*
Kumar et al. (2018) (19)	MODERATE	*Effect estimates comes from a small pilot program*	Shore et al. (2007) (30)	LOW	*Limited cost analysis (only savings related to telehealth/in person screening interviews considered, e.g. travel, accommodation etc.)*
Holst (2018) (45)	HIGH		Simon et al. (2001) (60)	MODERATE	*No discussion of uncertainty, estimates based on standard prices rather than the true cost of providing/accessing services*
Klein et al. (2018) (39)	HIGH		Simon et al. (2000) (59)	MODERATE	*No discussion of uncertainty*
Morriss et al. (2019) (42)	HIGH		Wang et al. (2006) (61)	LOW	*12-week budget impact study (no follow-up), effect estimates (retention) based on a clinical trial similar to the intervention: assumption made about reSET-O being as effective as a clinic-based PDT, potential for sponsor bias*
van Luenen et al. (2019) (16)	MODERATE	*Imputed missing data but 60% attrition rate, only retrospective cost estimates collected at the second post-test*	Mlcoch et al. (2015) (65)	MODERATE /LOW	*Effect estimate comes from two RCTs: one was ca 20 participants in the treatment arm, and the second RCT reported high non-adherence in the active arm*
Egede et al. (2018) (31)			Wilson (2008) (32)	MODERATE	*Possible selection and performance bias, different comparator used for effect estimates than in the cost-effectiveness analysis*
Jolstedt et al. (2018) (15)	HIGH		Abhulimen & Hirsch (2018) (75)	LOW	*Lack of information about the intervention, publication bias (source of funding not stated but device company named as author)*
Axelsson et al. (2018) (26)	HIGH		Lange et al. (2017) (76)	LOW	*Limited cost analysis (cost savings based on estimated average travel time saved)*
Topooco et al (2018) (63)	MODERATE	*Self-selecting sample (.>90% female), limited cost analysis, lack of comparator data at 6-month follow-up*	Nobis et al. (2018) (21)	MODERATE	*Did not include costs and saving related to comorbid conditions, imputed missing data but 29% attrition rate and short follow-up may have led to bias.*
Zhou et al (2019) (18)	LOW	*Effect estimate comes from a non-randomised study with a small sample size*			

Table 3: Study characteristics.

Study (year)	Intervention	Study design	Population	Cost perspective	Outcome	Main result
Hedman et al (2016)† (20) Sweden	iCBT	CUA	Adults with severe health anxiety in Sweden (n=158)	Societal	QALY	ICER $10,000 per QALY
Lindsäter et al (2019) (12) Sweden	iCBT	CUA	Patients with AD or ED (n=100)	Societal (healthcare in sensitivity analysis)	QALY	Dominant
Richards et al (2020) (43) UK	iCBT	CUA	New referrals to NHS IAPT service (n=361)	Healthcare	QALY	ICER: £29,764 per QALY
Baumann et al (2020) (13) Germany	iCBT	Model	Patients with unipolar depression	Societal	QALY	Dominant
Health Quality Ontario (2019) (73) Canada	iCBT	Model	Adults with a diagnosis of mild-moderate depression or anxiety disorder	Ontario Ministry of Health and Long-Term Care Perspective	QALY	ICER: $31,575 per QALY
Mohr et al (2019) (14) USA	iCBT	CC	Patients with MDD (n=312)	Narrow healthcare	Depression severity	Dominant
Nobis et al (2018) (21) Germany	iCBT	CUA	Adults with Type 1 or 2 DM & comorbid depressive symptoms (n=256)	Societal	QALY	ICER: €10,708 per QALY
Topooco et al (2018) (63) Sweden	iCBT	Intervention costing	Adolescents with depressive symptoms (n=70)	Healthcare	Depression severity	$430 per person, reduction in depression
Axelsson et al (2018) (26) Sweden	iCBT	CUA	Adults with severe health anxiety (n=132)	Societal	QALY	Unguided support was dominant compared to a waiting list group Guided support had ICER of £103,048 compared to waiting list group
Jolstedt et al (2018) (15) Sweden	iCBT	CEA	Children aged 8-12 with anxiety disorders (n=131)	Societal	Anxiety severity	Dominant
Van Luenen et al (2019) (16) Netherlands	iCBT	CUA	People with HIV & depressive symptoms (n=188)	Societal	QALY	Dominant
Mihalopoulos et al (2005) (23) Australia	iCBT	Model	People with panic disorder who consulted a GP	Healthcare	DALY	ICER: $3200 to $4300 per DALY
Holst et al (2018) (45) Sweden	iCBT	CUA	Adults with mild to moderate depression in primary care (n=90)	Healthcare and societal	QALY	ICER for TAU vs intervention: SEK 53,874 (societal), SEK 5371 (health)
Kraepelien et al (2018) (22) Sweden	iCBT	CUA	People aged 18–67 years with depressive symptoms (n=945)	Healthcare provider in primary care perspective (for the 3-month intervention period); 1yr societal costs	QALY	ICER: €8817 to €31,471 per QALY
Osborne et al (2019) (53) Australia	iCBT	Cost-benefit analysis	NA	N/A	Productivity gains	iCBT had better ratio of benefits to costs than face to face therapy or relaxation therapy

Axelsson et al (2020) (36) Sweden	iCBT	CUA	Adults with a principal diagnosis of SSD or hypochondriasis (n=204)	Societal	Health anxiety symptoms	iCBT had non-inferior outcomes comparted to face to face therapy and lower costs
Lalouni et al (2019) (17) Sweden	iCBT	CUA	Children (aged 8–12 years) diagnosed with FAPDs (n=90)	Societal	QALY	Dominant
Kolovos et al (2018) (25) Germany and Netherlands	iCBT	CEA & MA	Adults with clinical or subclinical depression (n=1426)	Societal	QALY	ICER: €32,706 to €81,155 per QALY Dominated at 12 months
Segal et al (2020) (72) Canada	iCBT, telephone and email support	RCT	Adults with one prior episode of MDD & residual depression symptoms (n=460)	Cost of health educator/ coach only	Depression severity	Intervention cost was modest and outcomes better for iCBT
Zhou et al (2019) (18) China	iCBT	RCT	Patients with OCD (n=28)	Societal	OCD severity	Dominant
Kumar et al (2018) (19) USA	iCBT	Model	People with anxiety based on GAD-7	Health & societal	QALY	Dominant
Harley (2006)† (71) Jersey	Videoconferencing	CEA	Patients with diagnosed schizophrenia and eating disorder (n=5)	Healthcare: fixed & variable costs	None	Cost saving
Jardine et al (2001)† (28) UK	Videoconferencing	N/A	N/A	N/A	None	Cost saving
Mielonen et al (2000)† (29) Finland	Videoconferencing	CC	Patients of inpatient care (Mental Health Department) (n=124)	Healthcare: fixed & variable costs	None	Cost saving
Shore et al (2007)† (30) USA	Videoconferencing	Model	Male Northern Plains American Indian veterans (n=53)	Direct costs	None	Cost saving (after initial period)
Shaw et al (2020) (33) USA	Video recording intervention	CEA	Persons with dementia and their caregivers (n=124; 68 dyads)	Healthcare (only intervention costs included)	Caregiver depression, caregiver competence	ICERs: $222 per improvement in depression, $437 per improvement in competence
Egede et al (2018) (31) USA	Videoconferencing	CUA	Veterans with MDD (n=241)	Intervention costs, travel time & lost income	QALY	Cost saving
Wilson et al (2008)* (32) USA	Lectures on depression using videoconferencing	CEA	Deaf & people with hearing problems (n=55)	Societal	Depression knowledge	Cost saving for similar outcomes
Olthuis et al (2018) (27) Canada	Video supported coaching	CEA	Primary caregivers for 6–12-year-olds exhibiting externalizing behavioural problems (n=172)	Societal	Child behavioural problems	Dominant
Joesch et al (2012)† (57) USA	Web-based outcome monitoring, CCBT	CUA	English/Spanish speaking adults in USA with anxiety-related disorder (n=1004)	Healthcare	QALY	Positive incremental net benefits reached at QALY threshold of $2500-5000
Blankers et al (2012)† (74) Netherlands	Internet-based motivational interviewing	CUA	Adults with alcohol use disorder (n=136)	Societal	QALY	ICER: €14,710 per QALY
Kooistra et al (2019) (40) Netherlands	Blended CBT (including web-sessions)	CUA	Patients with MDD in the acute phase of treatment in specialised mental health care (n=102)	Societal	QALY	High probability of cost-effectiveness from healthcare but not societal perspective
Lerner et al (2020) (49) USA	Telephone supported therapy	RCT with cost data included	Adult veterans who had work limitations resulting in at least 5% at-	N/A	Productivity, depression severity	Cost saving

			work productivity loss, and current MDD (n=253)			
Dukhovny et al (2013)† (56) Canada	Telephone-based peer support	prospectively planned CEA	High risk women in the first 12 weeks postpartum (n=610)	Societal perspective	PPD averted	$10,009 per case averted
Kafali et al (2014)† (58) USA	Telephone-based CBT	CEA	Adult Latinos (aged>18) with diagnosed depression (n=257)	Social cost	Reduction in depression	ICER: $70 per point reduction in depression score (vs TAU), dominant compared to face to face therapy. Cost per unit improvement on PHQ9 was $79.
Richards et al (2016)† (24) UK	Telephone supported therapy	CUA	Adults meeting ICD-10 criteria for depressive episodes (n=581)	Healthcare (NHS and social care)	QALY	ICER: £14,248 per QALY
Simon et al (2001)† (60) USA	Telephone monitoring	CEA	Adults who are high utilizers of general medical care with an HDRS score>15(depression) (n=407)	Total screening costs, outpatient and inpatient health services costs, costs of skilled nursing facility or home health care & prescription costs	Depression free days	ICER: $52 per depression free day
Simon et al (2000)† (59) USA	Telephone monitoring	CC	Patients starting new anti-depressant treatment (n=613)	Insurer perspective	Depression severity	Incremental cost of $83 and improved outcomes
Wang et al (2006)† (61) USA	Telephone care management	Model	Hypothetical cohort of 40-years-old workers	Societal perspective	QALY	ICER: $19,976 per QALY
Mukuria et al (2013)† (47) UK	CCBT and telephone support	CEA	Patients between 16-64, identified by their GP as likely to benefit from psychological therapies (n=403)	Societal perspective	QALY	£29,500 per QALY
Thase et al (2020) (55) USA	CCBT	CUA	Adults with MDD (n=154)	Healthcare	QALY	Dominant
Kaltenthaler et al (2006) (38) UK	CCBT	CEA	Patients in primary care with depression	N/A	QALY	ICER: €1801 per QALY
MIčoch et al (2015)* (65) Czech Republic	IT-aided relapse prevention programme	Markov cohort model	Patients with schizophrenia	Payer's & Public health insurance Perspective	Relapse, QALY	Dominant
Abhulimen & Hirsch (2018)* (75) USA	Digital behavioural health tool	CC	Medicaid consumers in Missouri (n=1514)	Payer's Perspective	None	Cost saving
Lange et al (2017)* (76) UK	Telepsychiatry	CC	Patients at Emergency Department Psychiatric Service (n=44)	Healthcare Perspective (N/A clearly)	None	Cost saving
Yilmaz et al (2019) (64) USA	Telepsychiatry	Model	Rural American Indian/Alaska Native populations	Narrow travel vs intervention costs for healthcare and patients	None	Cost saving
Lokkerbol et al (2014) (51) Netherlands	Telemedicine	Model	People aged 18–65 years	Direct medical cost	DALY	ICER falls from €13,775 to €11,361 when intervention is added
Morris et al (2019) (42) UK	Remote CBT	CUA	Adults with health anxiety (n=156)	Societal	QALY	Dominant

Klein et al (2018) (39) Netherlands	Remote CBT	CUA	Remitted adults with a history of MDD (264)	Societal	QALY	ICER: €230,816 per QALY
Horn et al (2016) (62) USA	Behavioural telehealth	Model	Rural Native American populations	Intervention & travel costs only	None	Cost saving
Smit et al (2011) (44) Netherlands	eHealth interventions	Model	18-69 years old classified as problem drinkers	Intervention delivery cost only	DALY	ICER: €16,053 per DALY
Lee et al (2017) (70) Australia	Internet supported school programme	Model	Students, aged 11–17 years with sub-threshold depression	Health and education sector perspective	DALY	High probability of being cost-effective if effect size 50-100% that of face to face therapy
Pil et al (2013) (54) Belgium	Telephone helpline	Model	People contacting the suicide helpline in 201	Societal	QALY	Dominant
Naveršnik & Mrhar (2013) (52) Slovenia	Web and phone support	Model	People newly diagnosed with depression/mixed anxiety or depression disorder or after a remission of >6 months (n=46)	Healthcare service	QALY	ICER: €1400 per QALY
Kählke et al (2019) (46) Germany	iSMI	CUA	Employees with elevated work-related stress (n=264)	Societal	QALY	Dominant
Lobban et al (2020) (50) UK	Direct messaging	RCT with cost data included	Relatives of people with psychosis or BD (n=800)	Direct intervention costs	Relative's distress	Higher costs and similar outcomes
Dowd et al (2018) (48) Ireland	Real time contact with clinicians	Model	Carers of people with dementia (n=28)	Formal and Informal care costs	QALY	ICER: €6927 to €110,930 per QALY
Hedman-Lagerlof et al (2019) (37) Sweden	iExp	CUA	Adults with fibromyalgia (n=140)	Societal	QALY	Dominant
Pot-Kolder et al (2020) (34) Netherlands	VR-CBT	CUA	Patients with a psychotic disorder & paranoid ideation (n=116)	Societal	QALY	ICER: €48,868 per QALY

Key:
†model *grey literature
ICD-10 – X, CUA – Cost-Utility Analysis, CEA – Cost-Effectiveness analysis, CC – Cost comparison, RCT – Randomized Clinical Trial, MA – meta analysis, HDRS – X, NHS – National Health Service, IAPT – Improving access to psychological therapies, MDD – major depressive disorder, OCD – obsessive compulsive disorder, AD – ED - eating disorder, SSD – somatic symptom disorder, BD- bipolar disorder FAPDS – X , GAD-7 – general anxiety disorder – 7 questionnaire

Figure 1: PRISMA flow chart.



Figure 2: Proportion of included studies that complied with applicable items of the Consolidated Health Economic Evaluation Reporting Standard (CHEERS) checklist.



Supplemental material

Table S1: Naslund et al. (2020) search strategy used in Medline

Search	Search terms
#1 (Mental disorders)	"serious mental illness" OR "serious and persistent mental illness" OR "severe mental illness" OR "mental illness" OR "mental health" OR "mental disorder" OR "schizophrenia" OR "bipolar disorder" OR "schizoaffective disorder" OR "major depressive disorder" OR "depression" OR "anxiety" OR "affective disorder" OR "psychotic disorders" OR "psychosis" OR "post-traumatic stress disorder" OR "PTSD" OR "stress disorder" OR "antipsychotics" OR "dementia" OR "epilepsy" OR "mental disorders"[MeSH terms] OR "anxiety disorders"[MeSH] OR "stress disorders, traumatic"[MeSH] OR "mood disorders"[MeSH] OR "depressive disorder"[MeSH] OR "schizophrenia and disorders with psychotic features"[MeSH] OR "psychotic disorders"[MeSH] OR "dementia"[MeSH] OR "epilepsy"[MeSH]
#2 (Substance-use disorders)	"alcohol" OR "substance use" OR "substance use disorder" OR "substance related disorder" OR "alcohol" OR "alcohol use disorder" OR "alcoholism" OR "amphetamine" OR "cocaine" OR "crack cocaine" OR "marijuana" OR "cannabis" OR "opioid" OR "heroin" OR "morphine" OR "street drugs" OR "drug abuse" OR "illicit drug" OR "recreational drugs" OR "substance-related disorders"[MeSH] OR "alcohol-related disorders"[MeSH] OR "amphetamine-related disorders"[MeSH] OR "cocaine- related disorders"[MeSH] OR "marijuana abuse"[MeSH] OR "opioid-related disorders"[MeSH] OR "street drugs"[MeSH] OR "crack cocaine"[MeSH]
#3	#1 OR #2
#4 (Digital technology)	"telemetry" OR "telemedicine" OR "telepsychiatry" OR "telehealth" OR "telecare" OR "Tele mental health" OR "connected health" OR "internet" OR "internet health" OR "web browser" OR "website" OR "web-based" OR "social media" OR "Facebook" OR "mobile health" OR "mobile technology" OR "mobile

	phone" OR "cellular phone" OR "cellphone" OR "smartphone" OR "text message" OR "text messaging" OR "wireless technology" OR "remote sensing technology" OR "remote consultation" OR "big data" OR "telemetry"[MeSH] OR "telemedicine"[MeSH] OR "internet"[MeSH] OR "web browser"[MeSH] OR "social media"[MeSH] OR "cellular phone"[MeSH] OR "text messaging"[MeSH] OR "wireless technology"[MeSH] OR "remote sensing technology"[MeSH]
#5 (Costs, cost-effectiveness, and economic evaluation)	"cost" OR "cost-effectiveness" OR "cost-benefit" OR "cost-minimisation" OR "cost-utility" OR "eco- nomic" OR "finance" OR "pricing" OR "spending" OR "expenditure" OR "costs and cost analysis"[MeSH] OR "cost-benefit analysis"[MeSH] OR "economics"[MeSH] OR "fees and charges"[MeSH]
#6 (Final search)	#3 AND #4 AND #5

Table S2: Grey literature search strategy

The grey literature search strategy was simplified from Naslund et al. (2020) search strategy to adapt for grey literature databases. It focused on the following terms:

1. tele* OR telehealth OR telepsychiatry OR remote OR technology OR digital
2. mental OR "mental health"
3. cost* OR economic* OR cost effective
4. 1 AND 2 AND 3

The term "digital" is not included in the search strategy of Naslund et al. (2020), however it has been added for grey literature searching after it returned relevant results during initial scoping.

Where databases had limited search functionality the search terms were further simplified and entered in following priority order:

i. telehealth AND mental AND cost
ii. tele* AND mental AND cost
iii. tele* AND mental AND economic
iv. tele* AND mental health AND cost
v. tele* AND mental health AND economic
vi. telepsychiatry and cost
vii. telehealth and cost
viii. telehealth and mental
ix. remote mental health
x. digital mental health
xi. technology mental health
xii. telepsychiatry
xiii. telehealth

The following databases and websites were searched on 4-10 November 2020: OpenSIGLE, Healthcare Management Information Consortium, National Technical Information Service, PsycEXTRA, NIHR innovation observatory, Institute of Health Economic, NHSEED, Substance Abuse & Mental Services Administration Evidence-Based Practices Resource Center, British Library, CADTH, Current Awareness Service for Health COPAC, EThOS, NDLTD, Nuffield Trust, OpenGrey, ISPOR conference, The Health Foundation.

Table S3: Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist

Section/Item	**No**	**Recommendation**
Title and abstract		
Title	1	Identify the study as an economic evaluation or use more specific terms such as "cost-effectiveness analysis", and describe the interventions compared.
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.

Introduction		
Background and objectives	3a	Provide an explicit statement of the broader context for the study.
	3b	Present the study question and its relevance for health policy or practice decisions.
Methods		
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.
Measurement of effectiveness	11a	Single study-based estimates: Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.
	11b	Synthesis-based estimates: Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.
Measurement and valuation of preference based outcomes	12	If applicable, describe the population and methods used to elicit preferences for outcomes.

Estimating resources and costs	13a	Single study-based economic evaluation: Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.
	13b	Model-based economic evaluation: Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.
Currency, price date, and conversion	14	Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.
Choice of model	15	Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended.
Assumptions	16	Describe all structural or other assumptions underpinning the decision-analytical model.
Analytical methods	17	Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.
Results		
Study parameters	18	Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.
Incremental costs and outcomes	19	For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.
Characterising uncertainty	20a	Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact of methodological assumptions (such as discount rate, study perspective).
	20b	Model-based economic evaluation: Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or

		other observed variability in effects that are not reducible by more information.
Discussion		
Study findings, limitations, generalisability, and current knowledge	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.
Other		
Source of funding	23	Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.

Source: Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D et al. (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 346 :f1049 doi:10.1136/bmj.f1049.

Table S4. CHEERS checklist: Results

Item N.	Lee et al. (2017)	Lokkerbol et al. (2014)	Naversnik et al. (2013)	Osborne at al. (2019)	Pil et al. (2013)	Kaelhke (2019)	Axelsson (2020)	Kolovos et al. (2018)	Dowd et al. (2018)	Pot-Kolder et al. (2020)	Smit et al. (2011)	Lerner et al. (2020)	Hedman-Lagerlof et al. (2019)	Lalouni et al. (2019)	Lobban et al. (2020)	Kaltenthaler et al. (2006)	Kraepelien et al (2018)	Mihalopoulos et al. (2005)	Horn et al. (2016)	Kumar et al. (2018)	Holts (2018)	Klein et al. (2018)	Morriss et al. (2019)	van Luenen et al. (2019)	Egede et al. (2018)	Jolstedt et al. (2018)	Axelsson et al. (2018)	Zindel et al. (2020)	Anonymous (2019)	Zhou et al. (2019)
1	Y	Y	Y	Y	Y	Y	P	Y	Y	Y	Y	N	Y	Y	P	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	Y
2	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
3a	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
3b	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	P	P	Y
4	Y	Y	P	P	P	Y	Y	Y	P	Y	Y	Y	Y	Y	Y	Y	Y	N	N	P	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
5	Y	Y	Y	Y	Y		Y	NA	Y	P	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
6	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	N
7	Y	Y	Y	P	Y	Y	Y	Y	Y	Y	Y,	Y	Y	Y	Y	Y	Y	Y	P	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
8	Y	P	P	Y	P	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	P	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	Y
9	Y	Y	NA	N	Y	NA	NA	NA	Y	NA	NA	NA	NA	NA	NA	Y	NA	NA	NA	NA	NA	Y	NA	NA	NA	NA	NA	NA	NA	NA
10	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	P	NA	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
11a	NA	NA	P	Y	NA	P	Y	NA	P	Y	NA	Y	Y	Y	Y	NA	P	P	P	Y	Y	P	Y	P	P	Y	Y	P	NA	P
11b	Y	Y	NA	NA	Y	NA	NA	Y	NA	NA	Y	NA	NA	NA	NA	Y	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Y	NA
12	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
13a	NA	NA	Y	Y	NA	Y	Y	NA	NA	Y	NA	Y	Y	Y	Y	NA	Y	Y	NA	NA	Y	Y	Y	Y	Y	Y	Y	P	NA	P
13b	Y	Y	NA	NA	Y	NA	NA	Y	Y	NA	Y	NA	NA	NA	NA	Y	NA	NA	P	P	NA	NA	NA	NA	NA	NA	NA	NA	Y	NA
14	Y	Y	Y	P	Y	Y	Y	Y	N	Y	Y	N	Y	Y	P	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	P	Y	N
15	Y	Y	NA	NA	Y	NA	NA	Y	Y	NA	Y	NA	NA	NA	NA	Y	NA	NA	N	Y	NA	NA	NA	NA	NA	NA	NA	NA	Y	NA
16	Y	Y	NA	NA	Y	NA	NA	Y	Y	NA	Y	NA	NA	NA	NA	Y	NA	NA	Y	Y	NA	NA	NA	NA	NA	NA	NA	NA	Y	NA
17	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	P	Y	Y	P	Y	Y	P	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	N
18	Y	P	NA	NA	Y	NA	NA	Y	Y	NA	Y	NA	NA	NA	NA	Y	NA	NA	P	P	NA	NA	NA	NA	NA	NA	NA	NA	Y	NA
19	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	P	Y	Y	Y	P	P	Y	Y	Y	Y	Y	Y	Y	N	Y	Y
20a	NA	NA	Y	P	Y	Y	Y	NA	NA	Y	NA	N	Y	Y	N	NA	Y	N	NA	NA	Y	Y	Y	Y	Y	Y	Y	N	NA	N
20b	Y	Y	NA	NA	NA	NA	NA	Y	Y	NA	Y	NA	NA	NA	NA	Y	NA	NA	Y	P	NA	NA	NA	NA	NA	NA	NA	NA	Y	NA
21	NA	NA	NA	NA	Y	NA	NA	NA	Y	NA	NA	N	NA	NA	N	NA	NA	NA	NA	NA	NA	Y	NA	NA	NA	NA	Y	NA	Y	NA
22	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
23	Y	P	N	P	P	Y	Y	Y	Y	P	P	Y	Y	Y	Y	Y	Y	P	P	Y	P	Y	Y	Y	Y	Y	Y	Y	N	P
24	Y	N	Y	N	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	N

Table S4. CHEERS checklist: Results (continued)

Item N.	Topooco et al. (2018)	Nbis et al. (2018)	Mohr et al. (2019)	Kooistra et al. (2019)	Baumann (2020)	Richards (2020)	Yilmaz et al. (2019)	Lindsater et al. (2019)	Shaw et al. (2020)	Thase et al. (2020)	Olthuis et al. (2018)	Richards (2016)	Hedman et al. (2016)	Joesch et al. (2012)	Harley (2006)	Jardine et al. (2001)	Mielonen et al. (2000)	Blankers et al. (2012)	Dukhovny et al. (2013)	Kafali et al. (2014)	Mukuria (2013)	Shore et al. (2007)	Simon et al. (2001)	Simon et al. (2000)	Wang et al. (2006)	Mlcoch et al. (2015)	Wilson (2008)	Abhulimen et al. (2018)	Lange et al. (2017)
1	N	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	N	Y	Y	Y	Y	Y	Y	N	P	Y	Y	Y	N
2	P	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	P	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	P	N	N
3a	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	P	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
3b	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	P	P	N	P	Y	P	Y	Y	P	N	Y	Y	Y	Y	N	P
4	Y	Y	Y	Y	P	Y	N	Y	Y	P	Y	Y	Y	Y	N	N	N	Y	Y	Y	P	N	P	P	N	P	Y	N	P
5	Y	Y	Y	Y	Y	Y	N	Y	N	N	Y	Y	Y	Y	Y	P	P	P	N	P	Y	Y	Y	Y	Y	Y	Y	N	N
6	N	Y	N	Y	Y	Y	N	Y	N	N	N	Y	Y	Y	N	N	N	Y	Y	N	Y	N	Y	Y	Y	Y	Y	P	N
7	Y	Y	Y	Y	Y	Y	P	Y	Y	Y	Y	Y	Y	Y	P	P	P	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	P	Y
8	N	Y	N	Y	Y	Y	P	Y	P	Y	Y	Y	P	Y	Y	P	N	Y	Y	Y	Y	P	Y	Y	Y	P	N	N	P
9	NA	NA	NA	NA	Y	NA	NA	NA	NA	NA	Y	NA	NA	N	NA	N	NA	NA	NA	NA	NA	N	NA	NA	Y	P	NA	NA	NA
10	Y	Y	Y	Y	Y	Y	NA	Y	P	Y	Y	Y	Y	Y	NA	NA	NA	Y	Y	Y	Y	NA	Y	Y	Y	Y	Y	NA	N
11a	P	P	Y	Y	NA	Y	NA	Y	P	N	Y	Y	Y	Y	N	N	N	Y	P	P	Y	NA	Y	Y	NA	P	P	P	N
11b	NA	NA	NA	NA	Y	NA	Y	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Y	NA	NA	NA	NA
12	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
13a	P	Y	Y	Y	NA	Y	NA	Y	P	P	Y	Y	Y	Y	P	NA	NA	Y	Y	Y	Y	NA	Y	P	NA	NA	P	P	N
13b	NA	NA	NA	NA	Y	NA	Y	NA	NA	NA	NA	NA	NA	NA	NA	N	Y	NA	NA	NA	NA	P	NA	NA	Y	Y	NA	NA	NA
14	N	Y	Y	Y	Y	Y	P	P	N	N	Y	Y	Y	Y	N	N	P	Y	Y	N	Y	P	P	P	Y	Y	N	N	P
15	NA	NA	NA	NA	Y	NA	Y	NA	NA	NA	NA	NA	NA	NA	NA	N	N	NA	NA	NA	NA	N	NA	NA	Y	Y	NA	NA	NA
16	NA	NA	NA	NA	Y	NA	P	NA	NA	NA	NA	NA	NA	NA	NA	N	N	NA	NA	NA	NA	P	NA	NA	Y	Y	NA	NA	N
17	Y	Y	P	Y	Y	Y	Y	Y	P	Y	Y	Y	Y	Y	N	N	N	Y	Y	Y	Y	N	Y	P	Y	P	P	P	N
18	NA	NA	NA	NA	Y	NA	P	NA	NA	NA	NA	NA	NA	NA	NA	N	N	NA	NA	NA	NA	P	NA	NA	Y	Y	NA	P	NA
19	P	Y	Y	Y	Y	Y	Y	Y	P	Y	Y	Y	Y	Y	P	P	P	Y	Y	Y	Y	P	Y	Y	Y	Y	N	N	N
20a	P	Y	N	Y	NA	Y	NA	Y	N	Y	Y	Y	Y	P	N	NA	NA	Y	Y	N	Y	NA	N	N	NA	NA	N	P	N
20b	NA	NA	NA	NA	Y	NA	Y	NA	NA	NA	NA	NA	NA	NA	NA	N	N	NA	NA	NA	NA	N	NA	NA	Y	Y	NA	NA	NA
21	NA	NA	NA	NA	NA	NA	NA	Y	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	Y	NA	NA	N	N
22	Y	Y	Y	Y	Y	Y	Y	Y	P	Y	Y	Y	Y	Y	P	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	P	P	P	P
23	Y	P	P	P	Y	Y	Y	Y	P	P	P	Y	P	Y	N	P	P	Y	P	P	Y	Y	P	P	P	N	N	N	N
24	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	N	N	Y	N	N		Y	N	Y	P	N	N	N	N

Note: Y = yes, N = not addressed, P = partially, NA = not applicable